从实验室到临床:生长抑素受体拮抗剂在神经内分泌肿瘤诊疗中的批判性评价
综述批判性评价放射性标记生长抑素受体(SSTR)拮抗剂在神经内分泌肿瘤分子影像和靶向放射性药物治疗中的应用。多种拮抗剂如[68Ga]Ga-NODAGA-JR11和[68Ga]Ga-NODAGA-LM3在研究中显示更高的肿瘤/本底比和病灶检出,尤其肝转移;治疗用[177Lu]Lu-DOTA-LM3和[177Lu]Lu-DOTA-JR11显示有希望的肿瘤摄取和剂量学特征。但证据多来自早期异质性研究,血液学毒性增加且缺乏生存获益的前瞻性证据。
要点
- SSTR拮抗剂在神经内分泌肿瘤成像中显示更高的肿瘤/本底比和病灶检出。
- 治疗用拮抗剂显示有希望的肿瘤摄取和剂量学特征,包括经治进展患者。
- 当前证据多为早期异质性研究,血液学毒性增加且无生存获益证据。
核心结论
- SSTR拮抗剂在神经内分泌肿瘤诊疗中具潜在优势,但证据有限且存在未解决的挑战。
研究设计与样本
- 本文为综述,批判性综合了放射性标记SSTR拮抗剂在神经内分泌肿瘤成像和治疗方面的现有数据。
主要发现
- [68Ga]Ga-NODAGA-JR11和[68Ga]Ga-NODAGA-LM3等拮抗剂在多项研究中显示更高的肿瘤/本底比和增强的病灶检出,尤其肝转移。
- [177Lu]Lu-DOTA-LM3和[177Lu]Lu-DOTA-JR11等治疗用拮抗剂显示有希望的肿瘤摄取和剂量学特征,包括既往治疗后进展的患者。
局限性
- 当前证据主要来自早期和异质性研究。
- 血液学毒性增加。
- 缺乏证明生存获益的前瞻性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neuroendocrine neoplasms are increasingly assessed using somatostatin receptor (SSTR) antagonists as an alternative to conventional agonists in molecular imaging and targeted radiopharmaceutical therapy. Radiolabeled SSTR antagonists, such as [68Ga]Ga-NODAGA-JR11 and [68Ga]Ga-NODAGA-LM3, have demonstrated higher tumor-to-background ratios and enhanced lesion detection in several studies, particularly in hepatic metastases. Therapeutically, radiolabeled antagonists such as [177Lu]Lu-DOTA-LM3 and [177Lu]Lu-DOTA-JR11 have shown promising tumor uptake and dosimetry profiles, including in patients with progressive disease after prior therapies. However, current evidence is largely derived from early-phase and heterogeneous studies. Increased hematologic toxicity and the absence of prospective evidence demonstrating a survival benefit remain key limitations. This review provides a critical synthesis of the available data, highlighting both the potential advantages and the unresolved challenges of SSTR antagonist-based imaging and therapy in neuroendocrine neoplasms.
引用
- Jafari E, Juweid ME, Raeisi A, et al. From Bench to Bedside: A Critical Appraisal of Somatostatin Receptor Antagonists in the Theranostic Management of Neuroendocrine Neoplasms. J Nucl Med. 2026. PMID: 42754346. doi:10.2967/jnumed.126.272687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。